Abstract
Since the effectiveness of gabexate mesilate in patients with acute pancreatitis is controversial, a metaanalysis of the published literature was conducted to address this problem. Five randomized trials were identified by our literature search. Three end points (mortality, complications, and complications requiring surgery) were evaluated. The results of our metaanalysis indicate that the treatment with gabexate mesilate does not affect mortality at 90 days (P=0.27), but significantly reduces the incidence of complications requiring surgery (odds ratio=0.61, 95% CI: 0.41–0.89;P<0.05) and of complications in general (odds ratio=0.69, 95% CI: 0.54–0.89;P<0.05). Because the drug proves to be beneficial only to a low proportion of the treated patients, its clinical impact seems to be small. A pharmacoeconomic evaluation shows that its use in all patients with acute pancreatitis would imply a very high cost for preventing each complication. The administration of the drug to select patients who are at higher risk of complications could have a better cost-effectiveness ratio. However, specific studies on this point are still lacking.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Buchler M, Malfertheiner P, Uhl W, Scholmerich J, Stockmann F, Adler G, Gaus W, Rolle K, Beger HG: Gabexate mesilate in human acute pancreatitis. Gastroenterology 104:1165–1170, 1993
Goebell H: Multicenter double-blind study of gabexate-mesilate (Foy) given intravenously in low dose in acute pancreatitis. Digestion 40:83, 1988
Pederzoli P, Cavallini G, Falconi M, Bassi C: Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A.): A prospective randomized double-blind multicenter study. Int J Pancreatol 14:117–124, 1993
Valderrama R, Perez-Mateo M, Navarro S, Vazquez N, San-Jose L, Adrian MJ, Estruch J: Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. Digestion 51:65–70, 1992
Yang CY, Chang-Chien CS, Liaw YF: Controlled trial of protease inhibitor gabexate mesilate (Foy) in the treatment of acute pancreatitis. Pancreas 6:698–700, 1987
Breslow NE, Day NE: Statistical Methods in Cancer Research. Vol II. The Design and Analysis of Cohort Studies. IARC Scientific Publications, Lyon, 1987, p 109
Woolf B: On estimating the relation between blood group and disease. Ann Hum Genet 9:251–253, 1955
Laupacis A, Sackett DL, Roberts RS: An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318:1728–1733, 1988
Messori A, Rampazzo R: Meta-analysis of clinical trials based on censored end-points: Simplified theory and implementation of the statistical algorithms on a microcomputer. Comput Progr Biomed 40:261–267, 1993
Simes RJ: Confronting publication bias: A cohort design for meta-analysis. Stat Med 6:11–29, 1987
Klein S, Simes J, Blackburn GL: Total parenteral nutrition and cancer clinical trials. Cancer 58:1378–1386, 1986
CCIS (Computerized Clinical Information System): Drugdex: Monograph on Aprotinin. Micromedex Inc., Vol 81, August 1994
Harada H, Miyake H, Ochi K, Tanaka J, Kimura I: Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis. Int J Pancreatol 9:75–79, 1991
Renner IG, Svage WT, Pantoja JP, Renner VJ: Death due to acute pancreatitis: A retrospective analysis of 405 autopsy cases. Dig Dis Sci 30:1005–1018, 1985
Sacks HS, Berrier J, Reitman D, Ancona-Bekr VA, Chalmers TC: Meta-analysis of randomized controlled trials. N Engl J Med 316:450–455, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Messori, A., Rampazzo, R., Scroccaro, G. et al. Effectiveness of gabexate mesilate in acute pancreatitis. Digest Dis Sci 40, 734–738 (1995). https://doi.org/10.1007/BF02064970
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02064970